Please select the market sector you are interested in.
Please select the university you are interested in.
Narrow your search with a few keywords.
Register now to receive technology alerts for your preferred market sector(s).
University: University of St Andrews
Sector(s): Life Sciences, Healthcare & Pharmaceuticals
About Opportunity:
Our invention comprises the combination of a cationic peptide with a bacterially-produced endopeptidase. The combination of these two molecules results in specific inhibition of Staphylococcus aureus MRSA or MSSA. Our results have shown that a specific and potent bactericidal effect is produced. Furthermore, the combination of the two components is synergistic, requiring far smaller quantities of the two components combined than either individual component to achieve the same degree of efficacy. The synergistic mode of action has the advantage that the two individual components act upon the bacterium by different mechanisms, therefore, it is expected that the combination would help prevent the rapid acquisition of resistance to the individual component antimicrobials. This is of particular importance for bacteria such as Staphylococcus aureus which are usually adept at acquiring resistance. The combination may also prove to be specifically efficacious against Staphylococcus aureus when impregnated into wound dressings or alternatively, used as a coating on medical devices or surgical instruments. The risk of spreading infection may be reduced by spraying or dipping any contact surfaces and medical or surgical instruments in order to disinfect any existing bacterial population or to inhibit bacterial re-colonisation
Key Benefits:
Combination antibacterial treatments are less likely to induce bacterial resistance
Combination treatment is synergistic and are more economical since they use less of each individual compound
Applications:
Surface cleaner to prevent spread of MRSA
Topical treatment of skin infections or wounds
Impregnated into wound dressings, plasters etc.
Coating on invasive medical devices, such as catheters, endoprostheses, grafts (including vascular grafts), stents, sutures, replacement joints, pins and plates for fixing bones, stoma devices (including a PEG-device) etc.
IP Status:
The University of St. Andrews has applied for International (PCT) patent protection (No. PCT/GB2007/001157). As yet, there are no commercial parties involved. The University would welcome enquiries from commercial parties interested in entering into a licensing arrangement. Additional information is available under a Confidentiality Agreement.
Please enter your name.
Please enter the name of the company you work for.
Please select the country you are in.
Please enter your email address.
Please enter your telephone number.
To help us process your enquiry faster please enter some details about the information you are interested in.
Please prove you are a human by completing this simple image recognition task.